Table 3.
Association of HIV infection with subtypesa of lymphoma diagnosed in Rwanda 2012–2016
| HIV+ | |||||
|---|---|---|---|---|---|
| N | n | % | ORb | 95%CI | |
| Controls | 1,196 | 54 | 4.5 | 1.0 | |
| Non‐Hodgkin lymphoma | |||||
| B‐cell | 159 | 16 | 10.1 | 2.5 | 1.3, 4.9 |
| Diffuse large B‐cell lymphoma | 56 | 16 | 28.6 | 6.6 | 3.1, 14.1 |
| Plasmablastic lymphoma | 6 | 5 | 83.0 | 106c | 12.1, 921 |
| Acute lymphobastic lymphoma (B‐cell ALL) | 33 | 0 | 0.0 | ||
| CLL/SLL | 21 | 0 | 0.0 | ||
| Burkitt lymphoma | 20 | 0 | 0.0 | ||
| Multiple myeloma | 11 | 0 | 0.0 | ||
| Follicular lymphoma | 5 | 0 | 0.0 | ||
| MALT lymphoma | 4 | 0 | 0.0 | ||
| Mantle cell lymphoma | 3 | 0 | 0.0 | ||
| T‐cell | 33 | 1 | 3.0 | 1.1 | 0.1, 9.4 |
| Acute lymphoblastic lymphoma (T‐cell ALL) | 20 | 0 | 0.0 | ||
| Anaplastic large cell lymphoma | 5 | 0 | 0.0 | ||
| Hodgkin lymphoma | |||||
| Classical | 76 | 10 | 13.2 | 5.2 | 2.3, 11.6 |
| Lymphocyte‐depleted | 4 | 2 | 50.0 | 20.3 | 2.3, 175 |
| Nodular sclerosis | 24 | 0 | 0.0 | ||
| Mixed cellularity | 17 | 3 | 17.6 | 12.0 | 2.7, 53.2 |
| Lymphocyte‐rich | 3 | 1 | 33.3 | 10.6c | 0.9, 118 |
| Nodular lymphocyte predominant | 0 | 0 | ‐ | ‐ | ‐ |
a
According to InterLymph hierarchy of WHO classification.12
b
Adjusted for gender [as appropriate], age and province.
c
Crude ORs and 95% CIs are shown, as adjusted model does not converge.